Qualigen Therapeutics, Inc. (QLGN)
NASDAQ: QLGN · IEX Real-Time Price · USD
0.293
-0.022 (-6.90%)
At close: Jul 19, 2024, 4:00 PM
0.272
-0.021 (-7.10%)
Pre-market: Jul 22, 2024, 9:12 AM EDT
Qualigen Therapeutics Employees
Qualigen Therapeutics had 4 employees as of December 31, 2023. The number of employees decreased by 34 or -89.47% compared to the previous year.
Employees
4
Change (1Y)
-34
Growth (1Y)
-89.47%
Revenue / Employee
$406,758
Profits / Employee
-$2,915,940
Market Cap
3.33M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 4 | -34 | -89.47% |
Dec 31, 2022 | 38 | -8 | -17.39% |
Dec 31, 2021 | 46 | 8 | 21.05% |
Dec 31, 2020 | 38 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Xylo Technologies | 84 |
Avinger | 72 |
Applied DNA Sciences | 55 |
Aptevo Therapeutics | 40 |
Healthcare Triangle | 31 |
Ensysce Biosciences | 7 |
ZyVersa Therapeutics | 7 |
60 Degrees Pharmaceuticals | 3 |
QLGN News
- 7 weeks ago - Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination - GlobeNewsWire
- 3 months ago - Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting - GlobeNewsWire
- 3 months ago - Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting - GlobeNewsWire
- 8 months ago - Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023 - GlobeNewsWire
- 9 months ago - Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors - GlobeNewsWire
- 9 months ago - Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer - GlobeNewsWire
- 10 months ago - Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023 - GlobeNewsWire
- 1 year ago - Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid Tumors - GlobeNewsWire